Avigbagene parvec

N/A

Report date: 2025/12/24 09:32:25

Base Information

Drug NameAvigbagene parvec
Drug Alias NameFLT-201FLT-200FLT200/201
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAVS3 vector
Mechanisms of ActionGene transferenceGlucosylceramidase replacements
TargetsGlucosylceramide
Therapy Area/IndicationsGaucher's disease type IGaucher Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesEuropeGermany +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesSpur Therapeutics
Inactive CompaniesN/A
Active IndicationsGaucher's disease type IGaucher Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A